Picture of Sharon Bio-Medicine logo

SHARONBIO Sharon Bio-Medicine Share Price

0.000.00%
in flag iconLast trade - 00:00
HealthcareMicro Cap

Momentum

Relative Strength (%)
1m-9.22%
3m-43.68%
6m-37.77%
1yr-52.02%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Margin7.49%

Financial Summary

Year End 31st MarUnit201920202021202220232024E2025ECAGR / Avg
Total RevenueIN₹m8,384.652,534.551,728.621,883.911,949.79n/an/a-31.83%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%n/an/an/a+25.81+7.52n/an/an/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202431st Mar 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Sharon Bio-Medicine EPS forecast chart

Profile Summary

Sharon Bio-Medicine Limited is an India-based pharmaceutical company. The Company is engaged in providing a range of pharmaceutical products and services, including animal toxicology and manufacturing of finished dosages. The Company's products include active pharma ingredients (APIs) and intermediates, and formulations. Its APIs and intermediates include Ketoconazole, Miconazole Nitrate, Sertaconazole Nitrate, Trimetazidine Di HCl, Nifedipine, Atomoxetine HCl, Trazodone HCl, Memantine HCI, Eperisone HCl, Glimepiride, Mosapride Citrate Dihydrate and Aripiprazole. Its formulation includes Aripiprazole tablets, Atorvastatin tablets, Azithromycin tablets, Betahistine tablets, Carbimazole tablets, Celecoxib capsules, Clopidogrel tablets, Carbocisteine capsules, Enalapril Maleate tablets, Donepezil tablets, Ezetimibe tablets and Famciclovir tablets. Its manufacturing facility is located at Navi Mumbai.

Directors

Last Annual
March 31st, 2023
Last Interim
March 31st, 2023
Incorporated
June 19th, 1989
Public Since
March 22nd, 2000
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
in flag iconNational Stock Exchange of India
Shares in Issue
5,755,625
Blurred out image of a map
Address
601, NAVI MUMBAI, 400705
Web
https://www.sharonbio.com/
Phone
+91 2267944000
Auditors
Shyam C. Agrawal & Co.

SHARONBIO Share Price Performance

Upcoming Events for SHARONBIO

Q4 2024 Sharon Bio-Medicine Ltd Earnings Release

Similar to SHARONBIO

Picture of Aarey Drugs and Pharmaceuticals logo

Aarey Drugs and Pharmaceuticals

in flag iconNational Stock Exchange of India

Picture of Aarti Drugs logo

Aarti Drugs

in flag iconNational Stock Exchange of India

Picture of Aarti Pharmalabs logo

Aarti Pharmalabs

in flag iconNational Stock Exchange of India

Picture of Abbott India logo

Abbott India

in flag iconNational Stock Exchange of India

Picture of Accent Microcell logo

Accent Microcell

in flag iconNational Stock Exchange of India

FAQ